SAN.PA - Sanofi
| Previous Close | 78.23 |
| Open | 78.39 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 78.27 - 79.50 |
| 52 Week Range | 62.88 - 80.44 |
| Volume | 3,059,629 |
| Avg. Volume | 2,444,010 |
| Market Cap | 98.022B |
| Beta (3Y Monthly) | 0.49 |
| PE Ratio (TTM) | 23.79 |
| EPS (TTM) | 3.33 |
| Earnings Date | Feb 7, 2019 |
| Forward Dividend & Yield | 3.03 (3.78%) |
| Ex-Dividend Date | 2018-05-11 |
| 1y Target Est | 81.81 |
- GlobeNewswire•2 days ago
Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
November 16, 2018 - The European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi.
Motley Fool•2 days agoZealand Pharma A/S - American Depositary Shares (ZEAL) Q3 2018 Earnings Conference Call Transcript
ZEAL earnings call for the period ending September 30, 2018.
- GlobeNewswire•2 days ago
Information concerning the total number of voting rights and shares
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général ...
GuruFocus.com•3 days agoWarren Buffett Buys Bank of America Corporation, JPMorgan Chase & Co, Oracle Corp, Sells ...
Third quarter portfolio update of Berkshire Hathaway
- Investor's Business Daily•3 days ago
This Potential Blockbuster Drug Is Plateauing — But Analyst Remains Bullish
Regeneron Pharmaceuticals' eczema treatment Dupixent appears to have hit a prescriber speed bump, an analyst said Wednesday.
- Investor's Business Daily•4 days ago
This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion Deal
AstraZeneca stock jumped Tuesday after the U.K.-based pharma giant said it would sell the U.S. rights to infant respiratory drug for $1.5 billion.
- GlobeNewswire•5 days ago
Sanofi: Disclosure of trading in own shares
Reporting EN This announcement is distributed by West Corporation on behalf of West Corporation clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy ...
- GlobeNewswire•7 days ago
Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
November 11, 2018 - New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions 2018. Praluent® (alirocumab) was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina (known as acute coronary syndrome, or ACS), and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C (low-density lipoprotein cholesterol) of 100 mg/dL or higher at baseline.
- Investor's Business Daily•11 days ago
Regeneron Crushes Profit Views, But Cuts A Key Piece Of Its Outlook
Regeneron Pharmaceuticals crushed Wall Street's third-quarter profit views by 66 cents, though sales of eye drug Eylea lagged outside the U.S.
Market Realist•10 days agoEurope: Key Growth Driver for Mylan
In the third quarter, Mylan (MYL) reported net sales of $1.04 billion from the European market, which is a flat performance on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the company has witnessed strong demand for branded generics and over-the-counter products in the European market. According to Mylan’s investor presentation, the company has a presence in 35 countries and offers more than 1,500 products in the European market. Mylan is already a leader in terms of value and volume in France and Italy’s generic drug markets.
- GlobeNewswire•10 days ago
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
New England Journal of Medicine publishes positive detailed results from Praluent ® (alirocumab) cardiovascular outcomes trial Praluent significantly reduced major adverse cardiovascular events by 15% ...
- PR Newswire•10 days ago
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial
PARIS and TARRYTOWN, N.Y., Nov. 7, 2018 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published positive detailed results of the 18,924-patient ODYSSEY OUTCOMES trial. The trial met its primary endpoint, showing that Praluent® (alirocumab) Injection significantly reduced the risk of major adverse cardiovascular events (MACE) in patients who had suffered an acute coronary syndrome (ACS), which included a heart attack or unstable angina.
- Thomson Reuters StreetEvents•10 days ago
Edited Transcript of SAN.PA earnings conference call or presentation 31-Oct-18 1:30pm GMT
Q3 2018 Sanofi SA Earnings Call
- Zacks•11 days ago
Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review
Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.
- Zacks•11 days ago
Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line
Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.
Motley Fool•11 days agoRegeneron Pharmaceuticals Inc (REGN) Q3 2018 Earnings Conference Call Transcript
REGN earnings call for the period ending September 30, 2018.
Market Realist•12 days agoTeva Pharmaceutical’s Performance in European Markets
In the third quarter, Teva Pharmaceutical’s (TEVA) European revenue fell ~12% YoY (year-over-year) to $1.2 billion from $1.38 billion. Its net European revenue fell YoY to $3.98 billion in the first nine months of this year from $4.02 billion.
- Reuters•12 days ago
Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA
The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi (SASY.PA) and Regeneron (REGN.O), the companies said on Tuesday. Dupixent was launched in the United States in April 2017 for the treatment of moderate-to-severe eczema in adults, and the product is seen as a key sales driver for both companies.
- Reuters•12 days ago
Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA
The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday. Dupixent was launched in the United States in April 2017 for the treatment of moderate-to-severe eczema in adults, and the product is seen as a key sales driver for both companies.
- GlobeNewswire•12 days ago
FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
November 6, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis.
- GlobeNewswire•12 days ago
Sanofi: Disclosure of trading in own shares
Reporting EN This announcement is distributed by West Corporation on behalf of West Corporation clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy ...
- Zacks•16 days ago
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
- Zacks•16 days ago
Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.
- Benzinga•17 days ago
The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...
- The Wall Street Journal•17 days ago
[$$] European Corporate Roundup
Disappointing results from Credit Suisse and Royal Dutch Shell set a slightly negative tone in European markets on another busy day of corporate news.
